Clinical Trials Sponsored by Novartis Pharmaceuticals

Total 21400 results

Novartis Pharmaceuticals

Active, not recruiting

A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

Retinitis Pigmentosa

Sweden
Novartis Pharmaceuticals

Completed

Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Psoriasis | Psoriatic Arthritis

Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N)

Non-small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia (SOAR)

Severe Aplastic Anemia

Spain, Italy, Hong Kong, Thailand, Korea, Republic of, Mexico, Turkey, India, Brazil
Novartis Pharmaceuticals

Completed

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Japan
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Non-Small Cell Lung Cancer

United States, Spain, United Kingdom, Japan, Turkey, Belgium, Germany, Netherlands, Canada, Singapore, Switzerland, Israel, Russian Federation, Korea, Republic of, Hong Kong, Lebanon, Italy, France, Portugal, Ireland
Novartis Pharmaceuticals

Completed

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)

Breast Cancer

United States, France, Spain, United Kingdom, Austria, Germany, Taiwan, Australia, Italy, Israel, Russian Federation, Korea, Republic of, Hong Kong, Thailand, Canada, Hungary, Japan, Lebanon, Belgium, Bulgaria, Greece, Argentina, Peru, Czech... and more
Novartis Pharmaceuticals

Completed

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Neovascular Age-related Macular Degeneration

Japan
Novartis Pharmaceuticals

Terminated

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Chronic Lymphocytic Leukemia (CLL)

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Hypercholesterolemia

China, Taiwan, Korea, Republic of, Singapore
Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (COMPLEEMENT-1)

Breast Cancer

United States, Belgium, Canada, Italy, Spain, United Kingdom, Austria, Czechia, Hungary, Malaysia, Saudi Arabia, Taiwan, Argentina, France, Israel, Netherlands, Russian Federation, Hong Kong, Thailand, Lebanon, Bulgaria, Denmark, Po... and more
Novartis Pharmaceuticals

Active, not recruiting

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

Argentina, Canada, Guatemala, Mexico, Brazil, Costa Rica, Dominican Republic, Panama
Novartis Pharmaceuticals

Completed

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

Asthma

South Africa, Hungary
Novartis Pharmaceuticals

Terminated

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (ORBIT)

Thyroid Eye Disease | Graves Orbitopathy

Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Relapsing Multiple Sclerosis (RMS)

China
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Sjögren Syndrome

United States, United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Canada, Colombia, Romania, Argentina, Chile, Brazil, S...
Novartis Pharmaceuticals

Completed

Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study

Neovascular Age-related Macular Degeneration

Portugal
Novartis Pharmaceuticals

Withdrawn

Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease

Dry Eye Disease
Novartis Pharmaceuticals

Terminated

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia. (READER)

Presbyopia

Canada, United States, Australia, Japan
Novartis Pharmaceuticals

Completed

Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US

Dry Eye Disease

United States
Novartis Pharmaceuticals

Completed

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Obesity

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Hepatic Failure

United States
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
Novartis Pharmaceuticals

Completed

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

BRAF Positive Metastatic Melanoma

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Novartis Pharmaceuticals

Withdrawn

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211)

Triple Negative Breast Cancer
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (EXCHANGE)

Multiple Sclerosis | Relapsing Multiple Sclerosis | Advancing Multiple Sclerosis

United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Completed

AScalate: Treat-to-target in Axial Spondyloarthritis (AScalate)

Axial Spondyloarthritis

Germany, France
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Advanced Hepatocellular Carcinoma

Taiwan, Canada, Italy, Korea, Republic of, Hong Kong, Germany, China, France
Novartis Pharmaceuticals

Completed

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings

Diffuse Large B-cell Lymphoma

United States
Novartis Pharmaceuticals

Completed

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)

Acute Myocardial Infarction

China, United States, South Africa, Italy, Spain, Croatia, Czechia, Hungary, Romania, Taiwan, Belgium, Germany, Netherlands, Austria, Denmark, United Kingdom, Thailand, Argentina, Israel, Australia, Bulgaria, France, Greece, Russian Federation and more
Novartis Pharmaceuticals

Completed

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Acute Graft Versus Host Disease

Belgium, Japan, Spain, France, Korea, Republic of, Canada, Italy, Denmark
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Non Small Cell Lung Cancer

Canada, Spain, Australia, Singapore, Germany, Italy, Korea, Republic of, Norway, Taiwan, United States, France
Novartis Pharmaceuticals

Completed

Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia

United Kingdom
Novartis Pharmaceuticals

Terminated

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria (MASTER)

Chronic Spontaneous Urticaria | Cold Urticaria | Cholinergic Urticaria

Germany
Novartis Pharmaceuticals

Completed

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Terminated

Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia

Amblyopia

United States, Australia, Canada
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ALK-positive NSCLC

Belgium, Spain, Italy, Australia, United States, Hong Kong, Canada, Singapore
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-15)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

Japan
Novartis Pharmaceuticals

Completed

Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.

Chronic Heart Failure

United States
Novartis Pharmaceuticals

Completed

Special Drug Use Surveillance for Entresto Tablets

Chronic Heart Failure

Japan
Novartis Pharmaceuticals

Completed

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (BOLERO-4)

Hormone Receptor Positive Breast Cancer

United States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) (MONALEESA-2)

Advanced, Metastatic Breast Cancer

United States, Canada, France, Italy, Spain, Taiwan, Hungary, Turkey, Belgium, Germany, Netherlands, Singapore, Austria, Czechia, Australia, Israel, Russian Federation, Sweden, United Kingdom, Korea, Republic of, Thailand, Lebanon, ... and more
Novartis Pharmaceuticals

Completed

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Acute Myeloid Leukemia

Japan, Taiwan, Hong Kong, Thailand, Korea, Republic of, Russian Federation, Vietnam
Novartis Pharmaceuticals

Completed

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Thailand
Novartis Pharmaceuticals

Completed

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Metastatic Melanoma

United States

3

Subscribe